BARCELONA, Spain–(BUSINESS WIRE)– Bioiberica’s combinatie van chrondroïtinesulfaat en glucosaminehydrochloride, een traag werkende geneesmiddel om osteoarthritis-symptomen te behandelen, is goedgekeurd als ethisch geneesmiddel in Frankrijk, Oostenrijk, Hongarije, Polen en Finland via een proces van wederzijdse erkenning uit Spanje.

‘Deze goedkeuring bevestigt dat Drugsagentschappen uit verschillende landen getuigen van de effectiviteit en veiligheid van de combinatie van chondroitinesulfaat en glucosaminehydrochloride van farmaceutische kwaliteit. Dit medicijn heeft bewezen pijn te verminderen en de mobiliteit te verbeteren bij mensen die lijden aan artrose van de knie en zou ook kunnen worden gebruikt als alternatief voor patiënten met cardiovasculaire of gastrointestinale problemen die chronisch geen ontstekingsremmende geneesmiddelen moeten krijgen’, stelt Dr Juan Gispert, directeur R&D van Bioiberica.

Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries

BARCELONA, Spain–(BUSINESS WIRE)–Bioiberica’s combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain.

‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica’s R&D director.

The principle study that guarantees its effectiveness is the MOVES clinical trial, published in the Annals of the Rheumatic Diseases,which concludes that the combination of chondroitin sulphate and glucosamine has an effectiveness comparable to the anti-inflammatory drug celecoxib after six months of treatment in patients with osteoarthritis and moderate to severe pain. It was observed that the combination of these two drugs relieves pain in a clinically relevant way. It also improves functional capacity, stiffness, relieves inflammation and joint effusion.

With these new approvals, a total of six European countries have approved Bioiberica brand’s combination of chondroitin sulphate and glucosamine hydrochloride. This year, the company plans to sign licensing and distribution agreements with companies specialised in the osteoarticular field to launch the product in the five countries where the drug was recently approved.

Bioiberica is the first European producer of chondroitin sulfate and international leader in joint health and chondroprotection thanks to a constant dedication and commitment to science and research. Vertically integrated, from the active ingredient to the finished product, Bioiberica offers its customers all their medical, scientific and commercial knowledge for the joint development of the market.